BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 549 filers reported holding BIO-TECHNE CORP in Q1 2022. The put-call ratio across all filers is 0.27 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $66,854,881 | -17.0% | 982,144 | -0.4% | 0.04% | -12.0% |
Q2 2023 | $80,528,587 | +9.7% | 986,504 | -0.3% | 0.05% | +4.2% |
Q1 2023 | $73,411,019 | -10.2% | 989,504 | +0.3% | 0.05% | -17.2% |
Q4 2022 | $81,747,671 | +15.4% | 986,342 | +97.9% | 0.06% | +9.4% |
Q3 2022 | $70,833,763 | -18.0% | 498,326 | +99.9% | 0.05% | -11.7% |
Q2 2022 | $86,422,000 | -27.1% | 249,311 | -8.9% | 0.06% | +5.3% |
Q1 2022 | $118,568,000 | -33.8% | 273,805 | -20.9% | 0.06% | -24.0% |
Q4 2021 | $179,121,000 | +8.4% | 346,233 | +1.5% | 0.08% | +4.2% |
Q3 2021 | $165,293,000 | -9.5% | 341,114 | -15.9% | 0.07% | -7.7% |
Q2 2021 | $182,606,000 | -8.7% | 405,557 | -22.6% | 0.08% | -14.3% |
Q1 2021 | $200,024,000 | +7.7% | 523,718 | -10.4% | 0.09% | +5.8% |
Q4 2020 | $185,667,000 | +1.2% | 584,685 | -21.1% | 0.09% | -10.4% |
Q3 2020 | $183,524,000 | -17.5% | 740,821 | -12.1% | 0.10% | -23.2% |
Q2 2020 | $222,437,000 | +38.0% | 842,337 | -0.9% | 0.12% | +12.6% |
Q1 2020 | $161,181,000 | -39.7% | 850,020 | -30.2% | 0.11% | -19.0% |
Q4 2019 | $267,254,000 | +3.2% | 1,217,495 | -8.0% | 0.14% | -2.1% |
Q3 2019 | $258,950,000 | -10.1% | 1,323,402 | -4.2% | 0.14% | -10.3% |
Q2 2019 | $287,913,000 | +3.2% | 1,380,936 | -1.7% | 0.16% | +0.6% |
Q1 2019 | $278,955,000 | +33.8% | 1,404,951 | -2.5% | 0.16% | +16.5% |
Q4 2018 | $208,480,000 | -26.7% | 1,440,576 | +3.4% | 0.13% | -12.5% |
Q3 2018 | $284,302,000 | +37.9% | 1,392,887 | -0.0% | 0.15% | +29.9% |
Q2 2018 | $206,098,000 | +3.6% | 1,393,027 | +5.8% | 0.12% | 0.0% |
Q1 2018 | $198,842,000 | +24.2% | 1,316,489 | +6.6% | 0.12% | +18.2% |
Q4 2017 | $160,044,000 | +17.8% | 1,235,379 | +9.9% | 0.10% | +13.8% |
Q3 2017 | $135,844,000 | -2.7% | 1,123,700 | -5.4% | 0.09% | -8.4% |
Q2 2017 | $139,603,000 | +402.0% | 1,188,108 | +334.3% | 0.10% | -51.3% |
Q1 2017 | $27,807,000 | -5.7% | 273,554 | -4.6% | 0.20% | -10.1% |
Q4 2016 | $29,490,000 | -6.2% | 286,786 | -0.1% | 0.22% | -6.5% |
Q3 2016 | $31,438,000 | -3.5% | 287,104 | -0.6% | 0.23% | -14.4% |
Q2 2016 | $32,570,000 | +82.9% | 288,812 | +53.3% | 0.27% | +88.2% |
Q1 2016 | $17,806,000 | +2.0% | 188,382 | -2.8% | 0.14% | +2.9% |
Q4 2015 | $17,449,000 | -1.3% | 193,878 | +1.4% | 0.14% | -10.3% |
Q3 2015 | $17,684,000 | -4.0% | 191,259 | +2.3% | 0.16% | +7.6% |
Q2 2015 | $18,413,000 | -22.3% | 186,993 | +4.5% | 0.14% | -20.8% |
Q1 2015 | $23,684,000 | +37.3% | 178,953 | -4.2% | 0.18% | +47.6% |
Q4 2014 | $17,255,000 | – | 186,728 | – | 0.12% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Broadcrest Asset Management, LLC | 300,000 | $24,489,000 | 21.05% |
Montanaro Asset Management Ltd | 388,800 | $31,737,744 | 5.02% |
Sandhill Capital Partners LLC | 502,447 | $41,014,775 | 3.74% |
Brown Capital Management | 3,160,892 | $258,023,614 | 3.66% |
DF DENT & CO INC | 3,275,617 | $267,388,640 | 3.62% |
Ownership Capital B.V. | 2,282,104 | $186,288,150 | 3.26% |
Jackson Square Partners, LLC | 1,361,789 | $111,162,836 | 3.24% |
STONE RUN CAPITAL, LLC | 88,135 | $7,194,460 | 3.20% |
Pembroke Management, LTD | 339,591 | $27,720,813 | 2.99% |
Summit Creek Advisors LLC | 283,693 | $23,157,860 | 2.90% |